Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

41. Heparin and derivatives in asthma and COPD: a meta-analysis

Heparin and derivatives in asthma and COPD: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

42. Low molecular weight heparin in addition to aspirin for the prevention of preeclampsia in women with a previous history: a meta-analysis

Low molecular weight heparin in addition to aspirin for the prevention of preeclampsia in women with a previous history: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

43. Low molecular weight heparin versusunfractionated heparin for neonatal sepsis complicated with disseminated intravascular coagulation: a systematic review and meta-analysis

Low molecular weight heparin versusunfractionated heparin for neonatal sepsis complicated with disseminated intravascular coagulation: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

44. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis

The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

45. Heparin for prevention of post ERCP pancreatitis: a meta-analysis

Heparin for prevention of post ERCP pancreatitis: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

46. Novel oral anticoagulants compared to low molecular weight heparin for the treatment of cancer associated venous thromboembolic events

Novel oral anticoagulants compared to low molecular weight heparin for the treatment of cancer associated venous thromboembolic events Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

47. Effectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: a systematic review

Effectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

48. Aspirin and heparin for the prevention of preeclampsia: a systematic review and network meta-analysis

Aspirin and heparin for the prevention of preeclampsia: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

49. Direct factor Xa Inhibitor compared to low molecular weight heparin for the treatment of cancer-associated thrombosis: a meta-analysis study

Direct factor Xa Inhibitor compared to low molecular weight heparin for the treatment of cancer-associated thrombosis: a meta-analysis study Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

50. Low molecular weight heparin use for the prevention of metastasis in preclinical animals models: A systematic review and meta-analysis

Low molecular weight heparin use for the prevention of metastasis in preclinical animals models: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

51. Low molecular weight heparin use and survival in cancer patients

Low molecular weight heparin use and survival in cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

52. Systematic review and network meta-analysis of full dose versus reduced dose low-molecular-weight heparin and other anticoagulant treatments in the treatment of cancer-associated venous thromboembolism

Systematic review and network meta-analysis of full dose versus reduced dose low-molecular-weight heparin and other anticoagulant treatments in the treatment of cancer-associated venous thromboembolism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2018 PROSPERO

53. General medicine: Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism

General medicine: Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism Article Text Commentary General medicine

2018 Evidence-Based Medicine

54. Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia:

Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: | CADTH.ca Find the information you need Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Frequency of Complete Blood Counts for Patients at Risk of Heparin-Induced Thrombocytopenia: Last updated: October 2, 2018 Project Number: RC1025-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac conditions? Key Message No relevant evidence-based guidelines were identified regarding the frequency of complete blood counts to monitor for heparin-induced thrombocytopenia during intravenous heparin infusions for cardiac

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

56. Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) Full Text available with Trip Pro

Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study) 29456608 2018 11 13 1751-1437 19 1 2018 Feb Journal of the Intensive Care Society J Intensive Care Soc Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). 80-82 10.1177/1751143717737408 eng Journal Article Review 2017 11 28 England J Intensive Care Soc 101538668 1751-1437 2018 2 20 6 0 2018 2 20 6 0 2018 2 20 6 1 ppublish 29456608 10.1177/1751143717737408 10.1177_1751143717737408

2017 Journal of the Intensive Care Society

57. Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines

Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Acetylsalicylic Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Acetylsalicylic (...) Acid versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis: Comparative Clinical Effectiveness and Guidelines Published on: November 14, 2017 Project Number: RC0941-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of acetylsalicylic acid versus low-molecular-weight heparin for venous thromboembolism prophylaxis in patients undergoing total hip or knee replacement? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

58. Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Full Text available with Trip Pro

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Heparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising are considered (...) important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if speed of injection affects the amount of pain and bruising where the injection is given, but results of these studies have differed and study authors have not reached a clear final conclusion. This is the first update of the review first published in 2014.To assess the effects of duration (speed) of subcutaneous heparin injection on pain

2017 Cochrane

59. Low Molecular Weight Heparin (LMWH) vs. Vitamin K Antagonist (VKA) for long-term treatment of venous thromboembolism in patients with cancer

Low Molecular Weight Heparin (LMWH) vs. Vitamin K Antagonist (VKA) for long-term treatment of venous thromboembolism in patients with cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

60. Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Full Text available with Trip Pro

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Heparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising are considered (...) important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if speed of injection affects the amount of pain and bruising where the injection is given, but results of these studies have differed and study authors have not reached a clear final conclusion. This is the first update of the review first published in 2014.To assess the effects of duration (speed) of subcutaneous heparin injection on pain

2017 Cochrane